Milestone Pharmaceuticals Stock Retained Earnings
| MIST Stock | USD 1.54 0.01 0.65% |
Milestone Pharmaceuticals fundamentals help investors to digest information that contributes to Milestone Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Milestone Stock. The fundamental analysis module provides a way to measure Milestone Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Milestone Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -326 M | -309.7 M | |
| Retained Earnings Total Equity | -185.7 M | -176.4 M |
Milestone | Retained Earnings |
Milestone Pharmaceuticals Company Retained Earnings Analysis
Milestone Pharmaceuticals' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Milestone Pharmaceuticals Retained Earnings | (326.03 M) |
Most of Milestone Pharmaceuticals' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Milestone Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Milestone Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Milestone Pharmaceuticals is extremely important. It helps to project a fair market value of Milestone Stock properly, considering its historical fundamentals such as Retained Earnings. Since Milestone Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Milestone Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Milestone Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Milestone Pharmaceuticals has a Retained Earnings of (326.03 Million). This is 135.01% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 103.49% higher than that of the company.
Milestone Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Milestone Pharmaceuticals' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Milestone Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Milestone Pharmaceuticals by comparing valuation metrics of similar companies.Milestone Pharmaceuticals is currently under evaluation in retained earnings category among its peers.
Milestone Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Milestone Pharmaceuticals from analyzing Milestone Pharmaceuticals' financial statements. These drivers represent accounts that assess Milestone Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Milestone Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 252.7M | 196.6M | 274.0M | 168.1M | 71.7M | 68.1M | |
| Enterprise Value | 133.4M | 125.2M | 160.6M | 163.0M | 109.8M | 207.7M |
Milestone Fundamentals
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 52.3 M | ||||
| Shares Outstanding | 53.27 M | ||||
| Shares Owned By Insiders | 0.69 % | ||||
| Shares Owned By Institutions | 56.91 % | ||||
| Number Of Shares Shorted | 382.56 K | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 91.95 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 5 M | ||||
| EBITDA | (60.81 M) | ||||
| Net Income | (59.69 M) | ||||
| Cash And Equivalents | 86.24 M | ||||
| Cash Per Share | 2.87 X | ||||
| Total Debt | 51.77 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.26 X | ||||
| Book Value Per Share | 0.48 X | ||||
| Cash Flow From Operations | (46.42 M) | ||||
| Short Ratio | 3.80 X | ||||
| Earnings Per Share | (1.01) X | ||||
| Target Price | 10.25 | ||||
| Number Of Employees | 47 | ||||
| Beta | 1.72 | ||||
| Market Capitalization | 81.77 M | ||||
| Total Asset | 75.23 M | ||||
| Retained Earnings | (326.03 M) | ||||
| Working Capital | 65.81 M | ||||
| Current Asset | 110.42 M | ||||
| Current Liabilities | 7.17 M | ||||
| Net Asset | 75.23 M |
About Milestone Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Milestone Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Milestone Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Milestone Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.